• Publications
  • Influence
Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial.
TLDR
Although quality of life was similar across the three treatment arms, the combination treatment was more toxic than the two drugs given singly and not more effective than single-agent vinorelbine or gemcitabine in the treatment of elderly patients with advanced NSCLC. Expand
Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials.
TLDR
Neutropenia during chemotherapy is associated with increased survival of patients with advanced non-small-cell lung cancer, and its absence might be a result of underdosing. Expand
Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis
TLDR
Pretreatment global QoL and IADL scores, but not ADL and comorbidity, have significant prognostic value for survival of elderly patients with advanced non-small-cell lung cancer who were treated with chemotherapy. Expand
Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study.
TLDR
The addition of weekly cisplatin to gemcitabine failed to demonstrate any improvement as first-line treatment of advanced pancreatic cancer and combined therapy produced more hematologic toxicity, without relevant differences in nonhematologic toxicity. Expand
Prevalence and management of pain in Italian patients with advanced non-small-cell lung cancer
TLDR
Pain is common in patients with advanced NSCLC, significantly affects QoL, and is frequently undertreated, so pain control should be a primary goal in clinical practice and in clinical trials and physicians should receive more training in pain management. Expand
Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial
TLDR
Palonosetron plus single-dose dexamethasone administered before common MEC regimens provide protection against acute and delayed CINV which is non-inferior to that of palonosettron plus dexamETHasone for 3 days, however, the major benefit of the single-day regimen occurs in patients receiving non-AC M EC regimens. Expand
Encephalopathy with status epilepticus during sleep or continuous spikes and waves during slow sleep syndrome: A multicenter, long-term follow-up study of 117 patients
TLDR
Electroclinical features, etiology, treatment and prognosis of 117 patients with encephalopathy with status epilepticus during sleep (ESES) or continuous spike and waves slow sleep (CSWSS) syndrome with a long-term follow-up are analyzed. Expand
Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety,
TLDR
The results showed that single-agent nab-paclitaxel 260 mg/m2 every 3 weeks is an effective and well tolerated regimen as second-line chemotherapy in HER2-negative, taxane-pretreated MBC patients, and that it produced interesting values of objective response rate and progression-free survival without the concern of significant toxicity. Expand
A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)
TLDR
The non-randomized design of this study suggests caution in the interpretation of these data, but in consideration of the low incidence of toxicity and the favourable results obtained in terms of clinical benefit, it may be worthwhile to test more active schedules of 5-FU (continuous infusion) in combination with gemcitabine. Expand
Early phase pharmacokinetics of doxorubicin (adriamycin) in plasma of cancer patients during single- or multiple-drug therapy.
TLDR
Doxorubicin (Adriamycin [AM]) was measured in plasma in the early distributive phase in 26 patients with different solid tumors, suggesting either a reduced metabolism of the parent compound or increased excretion of the reduced metabolite. Expand
...
1
2
3
4
5
...